[go: up one dir, main page]

EP4138997A1 - Dispositifs de thérapie vaginale par lumière et procédés d'utilisation correspondants - Google Patents

Dispositifs de thérapie vaginale par lumière et procédés d'utilisation correspondants

Info

Publication number
EP4138997A1
EP4138997A1 EP21793370.4A EP21793370A EP4138997A1 EP 4138997 A1 EP4138997 A1 EP 4138997A1 EP 21793370 A EP21793370 A EP 21793370A EP 4138997 A1 EP4138997 A1 EP 4138997A1
Authority
EP
European Patent Office
Prior art keywords
light
light sources
expandable member
vaginal
stiffening body
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21793370.4A
Other languages
German (de)
English (en)
Other versions
EP4138997A4 (fr
Inventor
Gregg Alan Klang
James Alan KRUNKLETON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cern Corp
Original Assignee
Cern Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cern Corp filed Critical Cern Corp
Publication of EP4138997A1 publication Critical patent/EP4138997A1/fr
Publication of EP4138997A4 publication Critical patent/EP4138997A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0601—Apparatus for use inside the body
    • A61N5/0603—Apparatus for use inside the body for treatment of body cavities
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/0624—Apparatus adapted for a specific treatment for eliminating microbes, germs, bacteria on or in the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0601—Apparatus for use inside the body
    • A61N5/0603—Apparatus for use inside the body for treatment of body cavities
    • A61N2005/0611—Vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/063—Radiation therapy using light comprising light transmitting means, e.g. optical fibres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/065—Light sources therefor
    • A61N2005/0651—Diodes
    • A61N2005/0652—Arrays of diodes

Definitions

  • the present application generally relates to medical devices and, more particularly, to vaginal light therapy devices, e.g., for treatment of bacterial and fungal infections, and to systems and methods for using such devices.
  • Vaginitis is characterized by inflammation of the vagina that results in discharge, itching and pain.
  • the cause is usually due to a change in the normal balance of vaginal bacteria or an infection.
  • the symptoms range from mucus-like discharge, itching, aching, pain during intercourse to odor.
  • the vaginal infections often have multiple causes that present challenging cases for treatment.
  • Bacterial vaginosis also known as vaginal bacteriosis or Gardnerella Vaginitis is a disease of the vagina caused by excessive bacteria growth. Common symptoms include increased vaginal discharge that often smells fishlike. The discharge is usually white or gray in color. Burning with urination may also occur. Itching is uncommon. Occasionally there may be no symptoms. Having bacterial vaginosis increases the risk of infection by a number of other sexually transmitted infections including HIV/AIDS. It also increases the risk of early delivery among pregnant women. Bacterial vaginosis is caused by an imbalance of the naturally occurring bacteria in the vagina. Diagnosis is suspected based on the symptoms and may be verified by testing the vaginal discharge and finding a higher than normal vaginal pH and large numbers of bacteria.
  • Bacterial vaginosis is often confused with a vaginal yeast infection. Usually treatment is through the use of antibiotics. Bacterial vaginosis is the most common vaginal infection in women of reproductive age. The percentage of women affected at any given time varies but can be as high as 35%. Antibiotics, administered either orally (e.g., metronidazole) or vaginally (e.g., clindamycin, metronidazole) are effective in treatment. About 10% to 15% of people, however, do not improve with the first course of antibiotics and recurrence rates of up to 80% have been documented.
  • metronidazole e.g., clindamycin, metronidazole
  • Recurrence rates are increased with sexual activity with the same pre-post treatment partner and inconsistent condom use although estrogen-containing contraceptives decrease recurrence.
  • Bacterial vaginosis is associated with up to a six-fold increase of HIV shedding.
  • Bacterial vaginosis is a risk factor for viral shedding and herpes virus type-2 infection.
  • Bacterial vaginosis may increase the risk infection or reactivation of HPV.
  • Candida is yeast, a type of fungus.
  • Yeast is usually present in the vagina in small numbers, and symptoms only appear with overgrowth.
  • Candida can multiply when an imbalance occurs, such as when the normal acidity of the vagina changes or when hormonal balance changes.
  • yeast infections may be a sign of more serious overarching health problem such as diabetes or a compromised immune system.
  • Recurrent infections may also be due to use of antibiotic medications. About 5-8% of women experience four or more episodes per year, diagnosed as recurrent vulvovaginal candidiasis.
  • Treatment for fungal infection can be topical or systemic.
  • Topical antifungals such as miconazole (over the counter Monistat), are generally considered as first-line therapy for uncomplicated, superficial, relatively localized fungal infections due to their high efficacy and low potential for systemic adverse effects.
  • Systemic antifungal agents are absorbed and delivered to the body through the blood stream.
  • the oral route is usually the safest, the most economical, and the easiest route for systemic antifungal drugs.
  • Oral fluconazole is available by prescription.
  • Topical antifungal creams and suppositories have fewer side effects than oral a systemically by the body, and only exert a localized effect on the genital region.
  • Antifungal pills affect the entire body, and side effects can include nausea, headaches, and abdominal pain.
  • topical medications can be messy and uncomfortable, while pills are comparatively simple.
  • Treatment using antifungal medication is ineffective in up to 20% of cases. Treatment for thrush is considered to have failed if the symptoms do not clear within 7-14 days.
  • the incidence of resistance to antifungal agents may be increasing, with drug- resistant fungal strains becoming increasingly common causes of infection in high-risk patient groups such as HIV/AIDS patients. Accordingly, alternative antifungal strategies are being actively sought.
  • Severe forms of infection are hard to treat, and frequently require more aggressive and long-term therapy, as is the case with chronic, recurrent cases. Additionally, incomplete treatments often result in drug resistant infections therefore full course of therapy should be adhered to.
  • Oral antifungal medications carry the risk of significant side effects, and many patients are allergic to or intolerant of these drugs.
  • Topical solutions can be messy and inconvenient.
  • a device that leverages this rising technology could potentially gain rapid acceptance in specific use cases as well as broader support among the general population simply wishing to avoid exposure to additional medications.
  • the present application is directed to medical devices and, more particularly, to vaginal light therapy devices, e.g., for treating bacterial and fungal infections, such as vaginitis, for treating pelvic inflammatory diseases, and/or for performing vaginal rejuvenation therapy, and to systems and methods for using such devices.
  • vaginal light therapy devices e.g., for treating bacterial and fungal infections, such as vaginitis, for treating pelvic inflammatory diseases, and/or for performing vaginal rejuvenation therapy, and to systems and methods for using such devices.
  • a light treatment device in accordance with an exemplary embodiment, includes an elongate member including a proximal end, a distal end sized for introduction into a vaginal canal, one or more light sources on the distal end, and an expandable member carried on the distal end and surrounding the one or more light sources.
  • the expandable member may be configured to emit light outwardly from the one or more light sources at one or more wavelengths, e.g., within a range of germicidal light.
  • the device may also include an inflator for expanding the expandable member from a contracted or delivery condition for introduction into a vaginal canal, and an expandable condition once inserted for delivering the light to treat one or more conditions.
  • a system for vaginal light therapy of a patient that includes a light treatment device comprising an elongate member including a proximal portion, a distal portion sized for introduction into a vaginal canal, one or more light sources, and an expandable member carried on the distal portion, the expandable member configured to emit light outwardly from the one or more light sources at one or more wavelengths within a range of germicidal light; and a controller comprising an inflator for expanding the expandable member from a delivery condition for introduction into a vaginal canal, and an expandable condition once inserted for delivering the light to treat one or more conditions.
  • a method for vaginal light therapy of a patient that includes inserting a distal end of an elongate light treatment device carrying an expandable member thereon into a vaginal canal with the expandable member in a contracted or delivery condition; expanding the expandable member within the vaginal canal; activating one or more light sources to emit light outwardly at one or more wavelengths, e.g., within a range of germicidal or other therapeutic light; and removing the device from the vaginal canal after treatment.
  • the device may be used to deliver low-level germicidal light, e.g., to treat targeted pathogens, for example, to treat fungal or bacterial vaginitis.
  • the device may be used to treat other conditions, such as pelvic inflammatory disease, and/or for performing vaginal rejuvenation therapy.
  • a device for vaginal light therapy of a patient that includes a stiffening body at least partially surrounding a central region; a flexible membrane carried by the stiffening body across the central region; and one or more light sources carried by one or both of the membrane and stiffening body configured to emit light outwardly at one or more wavelengths within a range of germicidal light.
  • a device for vaginal light therapy of a patient that includes a flexible membrane comprising a concave surface; a stiffening body extending at least partially surrounding a perimeter of the membrane and sized for introduction into a vaginal canal of the patient; and one or more light sources carried by one or both of the membrane and stiffening body configured to emit light outwardly at one or more wavelengths within a range of germicidal light.
  • the device may carry a power source coupled to the one or more light sources, e.g., including a battery and/or processor, to deliver power to the one or more light sources when activated to emit light.
  • the device may be connectable to an external power source and/or controller.
  • an appendage may extend from one end of the device that includes one or more leads coupled to the one or more light sources for delivering power to the one or more light sources from the external power source.
  • an external controller may be provided that is connectable to the appendage for delivering power to the one or more light sources, which may be activated manually or remotely by the patient.
  • a system for vaginal light therapy of a patient that includes a light treatment device comprising a flexible membrane, a stiffening body extending at least partially surrounding a perimeter of the membrane and sized for introduction into a vaginal canal of the patient, one or more light sources carried by one or both of the membrane or stiffening body configured to emit light outwardly at one or more wavelengths within a range of germicidal light; and a controller connectable to the device for activating the one or more light sources to deliver light therapy within the vaginal canal.
  • a light treatment device comprising a flexible membrane, a stiffening body extending at least partially surrounding a perimeter of the membrane and sized for introduction into a vaginal canal of the patient, one or more light sources carried by one or both of the membrane or stiffening body configured to emit light outwardly at one or more wavelengths within a range of germicidal light
  • a controller connectable to the device for activating the one or more light sources to deliver light therapy within the vaginal canal.
  • a device for vaginal light therapy of a patient that includes a malleable body sized for introduction into a vaginal canal of the patient; and one or more light sources carried by the body and configured to emit light outwardly at one or more wavelengths within a range of germicidal light.
  • the device may carry a power source coupled to the one or more light sources, e.g., including a battery and/or processor, to deliver power to the one or more light sources when activated to emit light.
  • the device may be connectable to an external power source and/or controller.
  • an appendage may extend from one end of the device that includes one or more leads coupled to the one or more light sources for delivering power to the one or more light sources from the external power source.
  • a method for vaginal light therapy of a patient includes providing a treatment device comprising an elongate member including a distal portion carrying an expandable member and one or more light sources; inserting the distal portion into a vaginal canal with the expandable member in a contracted condition; expanding the expandable member within the vaginal canal; activating the one or more light sources to emit light outwardly at one or more wavelengths within a range of germicidal light; and removing the device from the vaginal canal after treatment.
  • FIG. 1 shows an exemplary embodiment of a device for vaginal light therapy of a patient including an expandable member carried on a distal end of an elongate member, and an inflator for selectively expanding the expandable member.
  • FIGS. 2A and 2B are cross-sectional views of a subject’s anatomy showing the device of FIG. 1 being introduced into the subject’s vagina in a contracted condition (FIG.
  • FIG. 2A expanded within the vagina for delivering light therapy
  • FIG. 3 A shows another example of a device for vaginal light therapy of a patient including an expandable frame or stiffening body carrying a membrane and a plurality of LEDs.
  • FIG. 3B shows the device of claim FIG. 3 A including an appendage for connecting the device to an external power source or controller.
  • FIG. 4 is a cross-sectional view of a subject’s anatomy showing the device of FIGS. 3A and 3B introduced into the subject’s vagina for light therapy.
  • references to “a compound” includes a plurality of such compounds and reference to “the polymer” includes reference to one or more polymers and equivalents thereof known to those skilled in the art, and so forth.
  • FIG. 1 shows an exemplary embodiment of a vaginal therapy device 10 that includes a catheter, shaft, or other elongate member 20 including a proximal portion 22, a distal portion 24 carrying a balloon or other expandable member 30 and one or more light sources (not shown) for delivering light therapy to a subject, e.g., to treat bacterial or fungal infections, such as vaginitis, to treat pelvic inflammatory diseases, and/or to perform vaginal rejuvenation therapy, as described elsewhere herein.
  • bacterial or fungal infections such as vaginitis
  • pelvic inflammatory diseases e.ginitis
  • the distal portion 24 may be substantially rigid, semi rigid, malleable, or flexible, while having sufficient column strength to insert the distal portion 24 into the subject’s vagina 90, e.g., until a distal tip 25 of the elongate member 20 is disposed adjacent the subject’s cervix 92.
  • the proximal portion 22 may also be substantially rigid, semi-rigid, or flexible, e.g., having sufficient column strength to advance the distal portion 24 into the subject’s vagina while holding and/or manipulating the proximal portion 22.
  • the proximal portion 22 may include a handle (not shown), e.g., extending from and/or otherwise attached to the proximal portion 22 to facilitate manipulation of the device 10 during use.
  • the elongate member 20 may include one or more lumens, e.g., an inflation lumen (not shown) extending between the proximal and distal portions 22, 24 and communicating with an interior of the balloon 30 for delivering inflation media to expand the balloon 30 and/or for evacuating the inflation media to collapse the balloon 30.
  • an inflator device 50 may be coupled to the proximal end 22 of the elongate member 20, e.g., via a hose or other line 52, for delivering inflation media into and/or evacuating inflation media from the balloon 30 via the inflation lumen.
  • the proximal portion 22 may include a port 23 communicating with the inflation lumen that includes a connector for removably connecting the hose 52 to the proximal portion 22.
  • the elongate member 20 may include one or more additional lumens, e.g., carrying one or more wires, optical fibers, and the like (not shown) for delivering power or light to the one or more light sources on the distal portion 24.
  • the inflator may be integrated into the shaft 20, e.g., within a handle on the proximal portion 22 (not shown).
  • the device 10 may include a rigid or flexible “wand” carrying an uninflated, stretchable balloon 30 covering a desired length along the distal portion 24, e.g., as shown in FIG. 1 and 2 A.
  • the balloon 30 may include a proximal end 32 attached to the shaft 20, and an enclosed distal end 34 that extends over the distal tip 25.
  • the balloon may include an annular distal end (not shown) attached to the distal portion 24, e.g., adjacent the distal tip 25.
  • FIG. 2B shows the balloon 30 inflated, e.g., with air or other fluid, as described further elsewhere herein.
  • One or more LEDs, optic fibers, or other light sources may be mounted in the wall and/or otherwise positioned or carried on the distal portion 10 of the shaft 20 over the length covered by the balloon 30.
  • the light source(s) may be activated to irradiate the vaginal wall through the inflated balloon 30, e.g., similar to the devices disclosed in U.S. Patent No. 10,004,918, U.S. Publication No. 2018/ 0361170, and International Publication No. WO 2021/ 071973, the entire disclosures of which are expressly incorporated by reference herein.
  • the balloon 30 may be (i) thin walled and made of a material to allow light to pass without significant attenuation, e.g., material that is transparent to at least the wavelength(s) of light emitted by the light source, and (ii) inflated with a low-attenuation material such as a compressible fluid, such as air or carbon dioxide.
  • a low-attenuation material such as a compressible fluid, such as air or carbon dioxide.
  • one or more light sources may be mounted, embedded in, or otherwise fixed to the wall of the balloon 30.
  • a plurality of LEDs and the like may be attached to the wall of the balloon 30 that are spaced apart from one another to transmit light radially outwardly from the balloon 30.
  • a plurality of light fibers may be embedded in or otherwise attached to the wall of the balloon 30.
  • one or more light sources may be provided on the proximal portion 22 and/or on the inflator device 50 that may communicate light to the light fibers, e.g., via fibers within a lumen of the shaft 20 (not shown), with ends of the fibers arranged on the balloon 30 transmitting the light radially outwardly from the balloon 30.
  • an indicator or controller may be provided to inform the operator of the status of the balloon 30, e.g., based on the inflating volume and/or pressure.
  • the inflator device 50 may include a manual or motorized pump, a syringe, and the like (not shown), that may be coupled to a valve, e.g., on the connector 23 on the proximal portion 22 of the shaft 20.
  • the inflator device 50 may be configured to deliver inflation media through the inflation lumen of the shaft 20 into the interior of the balloon 30, e.g., to deliver a predetermined volume of inflation media to inflate the balloon 30 to a desired size.
  • the inflator device 50 may monitor the pressure of the inflation media being delivered, e.g., to ensure a maximum pressure is not exceeded.
  • one or more actuators may be provided on the proximal portion 22, e.g., on a handle attached to the proximal portion 22, which may be activated by the user to activate/deactivate the inflator device 50 and/or turn the light source(s) on and off, as desired.
  • a compressible gas or other fluid may be delivered via the inflator device 50 to expand the balloon 30 and dilate and/or otherwise shape the subject’s anatomy surrounding the vagina 90 before light delivery, e.g., to dilate the vagina and/or otherwise expose tissue surfaces for treatment.
  • the compressible fluid and elastic balloon may also allow the balloon 30 to conform at least somewhat to the user’s anatomy, e.g., to minimize gaps between the balloon and vaginal wall.
  • Exemplary gases may include carbon dioxide or other biocompatible gas (particularly for applications where rupture of the balloon 30 may expose the fluid to the subject’s vascular system). Assuming use of an ideal gas, the inflated volume may be inversely proportional to the pressure to which the balloon 30 is inflated.
  • a manual inflator device may include an actuator and visual indicia (not shown) to identify the volume being delivered, or a motorized inflator device may deliver fluid until the predetermined volume is delivered and then automatically shut off.
  • external imaging e.g., ultrasound, may be used to monitor inflation of the balloon 30 to confirm when a desired size and/or shape are attained.
  • valves may be provided within the shaft 20 that are coupled in series such that, once desired pressure, e.g., five psi is achieved, the inflator device 50 may automatically shut off.
  • the device 10 may include a relief valve (not shown) to release excess pressure and/or prevent over-inflation of the balloon 30 during use.
  • the balloon 30 may be made of an inelastic material to provide a balloon with a single volume and/or shape once inflated (i.e., the balloon does not expand appreciably with increased pressure once fully inflated).
  • the balloon 30 may have a desired shape configured to dilate and/or otherwise shape the vaginal wall, e.g., to enhance exposure to the light transmitted by the device.
  • the material may be reasonably strong with low light attenuation, such as cellophane, for example.
  • the balloon 30 may be inflated to a pressure that provides full expansion of the balloon 30 within any typical vaginal cavity, e.g., using a compressible fluid, such as carbon dioxide, or an incompressible fluid, that is non-attenuating to the light transmitted by the light source(s).
  • a compressible fluid such as carbon dioxide, or an incompressible fluid
  • no indicator to inform the operator of the balloon volume may be required if incompressible fluid is used given the fixed shape of the balloon.
  • one or more LEDs or other light sources may be activated to emit light from the shaft 20 through the and balloon wall to the vaginal wall.
  • compressible fluid may include carbon dioxide, nitrogen, and the like, e.g., in case the balloon ruptures and the gas enters the blood stream.
  • the stiff balloon material may be a thicker, more-robust material that substantially attenuates light.
  • one or more LEDs or other light sources may be mounted on or in the balloon wall.
  • an incompressible fluid such as water, may be used to inflate the balloon.
  • the devices described herein may be used by an individual on their own, e.g., at home or other non-medical setting.
  • the devices may be operated by a medical professional, e.g., in a doctor’s office, hospital, or other location, to provide one or more treatments delivering vaginal light therapy of a patient.
  • the distal portion 24 of the device 10 (carrying the balloon 30 and one or more light sources) may be inserted into a vaginal canal 90 with the balloon 30 in a contracted condition.
  • the balloon 30 may be expanded, e.g., by connecting the hose 52 of the inflator device to the proximal portion 22 and delivering inflation media, e.g., a predetermined volume of biocompatible fluid.
  • positioning and/or inflation of the balloon 30 may be monitored by the operator, e.g., using ultrasound or other external imaging, e.g., to ensure the balloon 30 is inflated to a desired size and/or shape.
  • the one or more light sources may then be activated to emit light outwardly at one or more wavelengths, e.g., within a range of non-UV or other suitable germicidal light.
  • the balloon 30 may be deflated, and the device 10 removed from the vaginal canal 90 after treatment.
  • the device 10 may sterilized and/or otherwise cleaned for subsequent reuse, or may be discarded as a single-use device.
  • FIGS. 3 A and 3B another embodiment of a vaginal light therapy device 110 is shown that is sized and/or shaped for insertion into a subject’s vagina 90 (e.g., as shown in FIG. 4).
  • the device 110 includes a supporting frame or body 120 carrying a membrane 130 and one or more light sources, e.g., a plurality of LEDs 140 mounted on or within one or both of the body 120 and membrane 130.
  • the light source(s) 140 may be configured to emanate light from one or both surfaces of the body 120 and/or membrane 130, e.g., at one or more wavelengths within a range of germicidal light, as described further elsewhere herein.
  • the stiffening body 120 may extend at least partially around a perimeter of the membrane 130, e.g., having an annular shape around the entire perimeter, as shown, or alternatively, having a “C” or other shape extending only partially around the perimeter (not shown).
  • the stiffening body 120 may be biased to a desired shape, e.g., to support the membrane 130 extending across a central region within the stiffening body 120, yet may be deflectable and/or deformable to allow the device 110 to be compressed for introduction.
  • the membrane 130 may be biased to a domed or other shape extending out of a plane generally defined by the stiffening body 120, e.g., defining an inner concave surface 132a and an outer convex surface 132b, which may be shaped to be placed against or adjacent desired vaginal surfaces.
  • One or more light sources 140 may be provided on or within one or both surfaces 132, e.g., to transmit light outwardly from the membrane 130 in all directions.
  • the light sources 140 may include individual LEDs or optic fibers extending from a source LED spaced apart from one another or otherwise distributed in a desired configuration relative to the membrane 130.
  • the membrane 130 may be translucent or transparent to the frequency range of light transmitted by the light source(s) 140, e.g., such that light may pass through the membrane 130 if the light sources are mounted on only one surface or are located within the membrane 130.
  • the membrane may include multiple layers of material, e.g., inner and outer membranes (not shown), with one or more light sources mounted or otherwise located between the membrane layers.
  • One or both membranes may be translucent or transparent to the frequency range of light transmitted by the light source(s).
  • a plurality of light sources may also be mounted on or within the stiffening body 120, if desired.
  • the stiffening body 120 and membrane 130 may be formed separately and permanently attached together or may be integrally formed from the same material, e.g., by molding, casting, and the like.
  • the body 120 and membrane 130 may be formed from elastomeric or other flexible, biocompatible material, e.g., silicone, that may be formed to a desired shape.
  • the stiffening body 120 may include one or more additional supports, e.g., wires, bands, and the like (not shown) embedded within and/or attached to one or more external surfaces of the body 120, e.g., to provide additional support and/or bias.
  • the stiffening body 120 may have sufficient bias to allow the device 110 to be rolled, folded, or otherwise compressed to a contracted condition to facilitate introduction, yet resiliently return towards an expanded shape when released to open the membrane 130 within the vaginal cavity 90, as shown in FIG. 4.
  • the membrane 130 may have sufficient elasticity to be compressed when the device 110 is rolled or folded, yet resiliently expand to the domed or other shape when released, e.g., to contact and, optionally, to at least partially dilate surrounding tissue.
  • the device 110 may include an appendage 150, which may be permanently and/or integrally formed with the stiffening body 120 or membrane 130, or may be removably connected to the device 110, e.g., by a connector (not shown) on the body 120.
  • the appendage 150 may include one or more leads 152 embedded within or otherwise carried by the appendage 150, which may be coupled to the light source(s) 140, e.g., to provide power to and/or otherwise operate the light source(s) 140.
  • the appendage 150 may be connected or connectable to an external power supply or controller 160, which may selectively activate the light source(s) 140 during use.
  • the light sources 140 are optic fibers
  • the leads 152 may include optic fibers that may be optically coupled to the fibers within the device 110, and one or more LEDs or other light sources may be provided within the controller 160.
  • a connector may be provided on one or both ends of the appendage 150, e.g., a first end that connects to the device 110 and a second end that connects to the power supply/controller 160. Alternatively, one or both ends may be permanently connected to the device 110 or the controller 160.
  • the appendage 150 may include one or more additional LEDs or other light sources (not shown), e.g., along an inner curve, to radiate the introitus and vulvar regions of the patient.
  • the appendage 150 may be biased to a curved shape yet may be sufficiently flexible to facilitate introduction and/or removal of the device 110.
  • one end of the stiffening body may include an integral extension that provides the appendage 150.
  • the appendage 150 may simply be a cable or other tether for connecting the device 110 to the power sour ce/contr oiler 160.
  • the device 110 may include one or more of a controller, e.g., for operating the light source(s) 140 in a desired manner, a battery or other power source, and/or a wireless communications interface (not shown) carried on or in the device 110.
  • such components may be embedded in the membrane 120, mounted on the stiffening body 130, and/or carried on an appendage 150 extending from the stiffening body 120
  • the device 110 may be rolled, folded, or otherwise compressed into a contracted configuration, e.g., manually or using an insertion tool that constrains the device 110, a 90.
  • the device 110 may be released, whereupon the stiffening body 120 may resiliently deploy into an expanded configuration, which may position the membrane 130, and consequently, the light source(s) 140 adjacent desired tissue regions of the vagina 90 and/or vaginal canal.
  • the light source(s) 140 may then be activated to treat an infection and then removed by the user, similar to other embodiments herein and in the applications incorporated by reference herein.
  • the device 110 may have a length that is greater than its width, e.g., such that a first end of the device 110 may be positioned against or adjacent the cervix 92 while a second opposite end is positioned within the entrance to the vaginal cavity, e.g., such the appendage 150 extends from the vagina 90 (if provided).
  • the first end may have a curved and/or concave shape, e.g., to conform to the shape of the cervix 92, which may facilitate proper positioning of the device 110.
  • the second end may include one or more features, e.g., tabs or holds, which may facilitate gripping the device 110 during introduction and/or removal after use.
  • a device for vaginal light therapy of a patient may be provided that includes a malleable body sized for introduction into a vaginal canal of the patient, and one or more light sources carried by the body and configured to emit light outwardly at one or more wavelengths within a range of germicidal light.
  • the body may include an internal power source and/or controller, which may be used to selectively activate the light source(s).
  • an appendage may extend from one end of the body that includes one or more leads coupled to the one or more light sources for delivering power to the one or more light sources from an external power source and/or controller, similar to other embodiments herein.
  • the malleable material of the body may be manually manipulated to a desired shape, which may facilitate introduction and/or position of the device within the user’s vaginal canal for light therapy.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Radiation-Therapy Devices (AREA)

Abstract

L'invention concerne des dispositifs, des systèmes et des méthodes pour la thérapie vaginale par lumière d'un sujet à l'aide d'un dispositif portant un élément expansible et une ou plusieurs sources de lumière. Une extrémité distale du dispositif portant sur lui l'élément expansible est introduite dans un canal vaginal, l'élément expansible étant dans un état contracté, l'élément expansible est déployé à l'intérieur du canal vaginal, la ou les sources de lumière sont activées pour émettre de la lumière vers l'extérieur à une ou plusieurs longueurs d'onde dans une plage de lumière germicide ou autrement thérapeutique ; et le dispositif est retiré du canal vaginal après le traitement.
EP21793370.4A 2020-04-20 2021-04-20 Dispositifs de thérapie vaginale par lumière et procédés d'utilisation correspondants Pending EP4138997A4 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063012708P 2020-04-20 2020-04-20
US202063012700P 2020-04-20 2020-04-20
US202017001609A 2020-08-24 2020-08-24
PCT/US2021/028235 WO2021216605A1 (fr) 2020-04-20 2021-04-20 Dispositifs de thérapie vaginale par lumière et procédés d'utilisation correspondants

Publications (2)

Publication Number Publication Date
EP4138997A1 true EP4138997A1 (fr) 2023-03-01
EP4138997A4 EP4138997A4 (fr) 2024-04-24

Family

ID=78270004

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21793370.4A Pending EP4138997A4 (fr) 2020-04-20 2021-04-20 Dispositifs de thérapie vaginale par lumière et procédés d'utilisation correspondants

Country Status (2)

Country Link
EP (1) EP4138997A4 (fr)
WO (1) WO2021216605A1 (fr)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0900461D0 (en) * 2009-01-12 2009-02-11 Photocure Asa Photodynamic therapy device
US20100298757A1 (en) * 2009-05-19 2010-11-25 Ams Research Corporation Adjuvant enhanced ablation
GB201221123D0 (en) * 2012-11-23 2013-01-09 Photocure As Device for photodynamic treatment
EP3019238A4 (fr) * 2013-07-10 2017-03-29 Oxys AG Dispositifs et méthodes de distribution d'énergie thérapeutique
US10004918B2 (en) * 2014-07-03 2018-06-26 Gregg Alan Klang LED based vaginal light therapy device
WO2017070155A1 (fr) * 2015-10-19 2017-04-27 Christoph Scharf Dispositifs pour l'émission de lumière thérapeutique réglée de manière répétée et dispositifs pour le traitement de l'empoisonnement au monoxyde de carbone
GB201522398D0 (en) * 2015-12-18 2016-02-03 Photocure As Device for photodynamic therapy
KR20190015357A (ko) 2016-05-31 2019-02-13 세다르스-신나이 메디칼 센터 체내 자외선 치료

Also Published As

Publication number Publication date
EP4138997A4 (fr) 2024-04-24
WO2021216605A1 (fr) 2021-10-28

Similar Documents

Publication Publication Date Title
US11819245B2 (en) Apparatus and methods for accessing and sealing bodily vessels and cavities
CN1163279C (zh) 产前准备和易于分娩的装置以及产前准备的操练方法
US10245074B2 (en) Apparatus and methods for accessing and sealing bodily vessels and cavities
US10004918B2 (en) LED based vaginal light therapy device
JP2022550659A (ja) 子宮異常出血制御システム及び方法
US12251570B2 (en) Light-based vaginal therapy devices and methods for use
JP2016536101A (ja) 子宮頸部安定化デバイス
US20250312616A1 (en) Light-based vaginal therapy devices and methods for use
CN111148543A (zh) 用于具有对准和顺应性加压的外翻导管的设备和方法
WO2021216605A1 (fr) Dispositifs de thérapie vaginale par lumière et procédés d'utilisation correspondants
EP3313513B1 (fr) Dispositif de luminothérapie vaginale basé sur la lumière
US20250170416A1 (en) Light-based vaginal therapy devices and methods for use
US20240407941A1 (en) Vaginal pessary
WO2025080734A1 (fr) Dispositifs de luminothérapie vaginale et procédés d'utilisation
CN113967309A (zh) 用于妇产科产道消炎用药的装置
WO2023041956A1 (fr) Dispositif endovaginal destiné à la correction de la vessie et du prolapsus utérin incorporant un système d'auto-lavage doté de douches vaginales
HK1024644B (en) Delivery preparation and facilitation device and preparatory gymnastics
MXPA99008930A (en) Delivery preparation and facilitation device and preparatory gymnastics

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20221118

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20240325

RIC1 Information provided on ipc code assigned before grant

Ipc: A61M 29/00 20060101ALI20240319BHEP

Ipc: A61N 5/06 20060101AFI20240319BHEP